Qube Research & Technologies LTD Seagen Inc. Transaction History

Qube Research & Technologies LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$191.51 - $216.16 $9.18 Million - $10.4 Million	-47,954 Reduced 21.27%	177,516 $37.7 Million
Q2 2023 Aug 14, 2023	BUY	$187.64 - $206.25 $29.2 Million - $32.1 Million	155,804 Added 223.64%	225,470 $43.4 Million
Q1 2023 May 15, 2023	BUY	$127.59 - $203.08 $8.89 Million - $14.1 Million	69,666 New	69,666 $14.1 Million
Q3 2022 Nov 14, 2022	BUY	$135.27 - $180.11 $29.5 Million - $39.3 Million	218,085 New	218,085 $29.8 Million
Q3 2021 Nov 12, 2021	SELL	$142.45 - $169.82 $560,540 - $668,241	-3,935 Closed	0 $0

Q2 2021 Aug 13, 2021	SELL	$135.08 - $161.1 $12.3 Million - $14.6 Million	-90,806 Reduced 95.85%	3,935 $621,000
Q1 2021 May 14, 2021	BUY	$137.51 - $190.8 $7.57 Million - $10.5 Million	55,079 Added 138.87%	94,741 $13.2 Million
Q4 2020 Feb 16, 2021	BUY	$164.63 - $211.93 $6.53 Million - $8.41 Million	39,662 New	39,662 $6.95 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.